Gene · 4102
Papers3,353
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 3,353
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification and Validation of an Autophagy-Related Gene Signature for Prognostic Prediction and Immunotherapy Response in Esophageal Squamous Cell Carcinoma. | Cancers (Basel) | 2026 | 41681864 | PubTator, text mining | PubMed |
| Smoking Behavior Is Associated With an Altered Immune Landscape in Prostate Cancer: Implications for Patient Outcomes. | Prostate | 2026 | 41664985 | PubTator, text mining | PubMed |
| Targeting hepatocellular carcinoma with MAGE-A3-specific TCR-engineered T cells: A therapeutic approach. | Int Immunopharmacol | 2026 | 41655433 | PubTator, text mining | PubMed |
| A data-driven cartography of NSCLC vaccine research: Quantifying the paradigm shift toward immuno-oncology combination therapies. | Hum Vaccin Immunother | 2026 | 41630477 | PubTator, text mining | PubMed |
| Melanoma antigen genes A1 and A3 as predictors of treatment response and survival in HCV-associated hepatocellular carcinoma: a prospective study. | BMC Gastroenterol | 2026 | 41566414 | PubTator, text mining | PubMed |
| <p>Tumor microenvironment in bone sarcomas: Implications for immunotherapy and emerging therapeutic vulnerabilities (Review)</p>. | Oncol Rep | 2026 | 41543186 | PubTator, text mining | PubMed |
| Serum cancer testis antigen MAGEA3-IgG serves as a diagnostic biomarker in lung adenocarcinoma. | Clin Transl Oncol | 2026 | 41489697 | PubTator, text mining | PubMed |
| Cardiovascular complications of cellular immunotherapies and associated risk factors. | NPJ Cardiovasc Health | 2025 | 41776340 | PubTator, text mining | PubMed |
| mRNA vaccines transform personalized lung cancer treatment. | Front Immunol | 2025 | 41766818 | PubTator, text mining | PubMed |
| Integrated analysis of single-cell and bulk RNA-seq reveals MAGEA3/6-associated immune subtypes and key immune genes in gastric cancer. | PLoS One | 2025 | 41452900 | PubTator, text mining | PubMed |
| CLDN22 Serves as a Novel Prognostic Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis. | Int J Genomics | 2025 | 41425851 | PubTator, text mining | PubMed |
| Identification of cancer-associated fibroblast subpopulation and construction of an immunotherapy signature for gastric cancer. | Transl Cancer Res | 2025 | 41234876 | PubTator, text mining | PubMed |
| S100A9 enhances tumor immune suppression and cancer cell survival in small cell lung cancer. | Cell Death Dis | 2025 | 41173834 | PubTator, text mining | PubMed |
| Design, synthesis, and evaluation of A therapeutic vaccine candidate against lung cancer based on multi-epitopes of MAGE-A3, TGF-β2, and VEGF-A. | BMC Cancer | 2025 | 41126072 | PubTator, text mining | PubMed |
| Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer. | ESMO Open | 2025 | 41101155 | PubTator, text mining | PubMed |
| Individualized mRNA Vaccines in Melanoma-Where Do We Stand? | Vaccines (Basel) | 2025 | 41012188 | PubTator, text mining | PubMed |
| ImmuniT Platform for Improved Neoantigen Prediction in Lung Cancer. | Vaccines (Basel) | 2025 | 41012124 | PubTator, text mining | PubMed |
| Nodal Spread Prediction in Human Oral Tongue Squamous Cell Carcinoma Using a Cancer-Testis Antigen Genes Signature. | Int J Mol Sci | 2025 | 41009820 | PubTator, text mining | PubMed |
| Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies. | Cells | 2025 | 41002441 | PubTator, text mining | PubMed |
| Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines. | Cells | 2025 | 41002418 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4102/papers?page=2